Sajith Wickramasekara, Benchling via YouTube

Meet Bench­ling, the lat­est uni­corn seek­ing to rev­o­lu­tion­ize the way sci­en­tists do work with the help of the cloud

There’s an­oth­er uni­corn in biotech land, as Bench­ling and its lead­ing R&D cloud plat­form pull in a $200 mil­lion Se­ries E to help sci­en­tists ac­cel­er­ate drug de­vel­op­ment. In do­ing so, the com­pa­ny hit a lofty $4 bil­lion val­u­a­tion — near­ly five times what it was worth around this time last year, ac­cord­ing to Forbes.

De­spite the fact that drug de­vel­op­ment is be­com­ing sig­nif­i­cant­ly more com­plex, the in­dus­try con­tin­ues to run on pa­per, emails and spread­sheets, co-founder and CEO Sajith Wick­ra­masekara said in a video on Bench­ling’s web­site. The for­mer MIT stu­dent sought to change that by cre­at­ing soft­ware that al­lows sci­en­tists to bet­ter track, mod­el and fore­cast their work.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.